RVMD

161.8801.54%
SM

Stephen M. Kelsey

Senior Advisor

Dr. Stephen M. Kelsey, also known as Steve, M.D., MB ChB, FRCP, FRCPath, has been Member of the Advisory Board of Tubulis GmbH since January 2026. He is Director of Delphia Therapeutics, Inc. from December 2025. Dr. Kelsey is Director of Circle Pharma, Inc. Dr. Kelsey was Independent Director of Circle Pharma, Inc. from December 2022. He served as Member of Scientific Advisory Board of Autobahn Labs, Inc. until December 2025 and serves as its Advisor. He serves as Member of Scientific Advisory Board at Remix Therapeutics Inc. since July 2022. He serves as Independent Director at Jiya Acquisition Corp since November 18, 2020. Dr. Kelsey had been President of Research and Development at Revolution Medicines, Inc. since March 20, 2017 until July 1, 2026 and serves as Senior Advisor since July 1, 2026. Dr. Kelsey served as President of Onkaido Therapeutics, a Moderna Venture focused on oncology mRNA therapeutics for cancer from 2014 to March 2017. He has held senior positions at Medivation, Geron and Genentech, where he played a significant role in the development of Perjeta, Kadcyla and Erivedge. He has had key roles in the development of many oncology therapeutics including imetelstat. He served as Senior Vice President of Projects of Medivation, Inc. from May 2013 to 2014. He was Senior Vice President of new products at Medivation (acquired by Pfizer). Dr. Kelsey has experience in the biopharmaceutical industry, working with conventional small molecules, beyond rule of five molecules, antibodies, antibody-drug conjugates, DNA oligonucleotides and mRNA platforms and has driven multiple industry and industry-academia collaborations to provide better drugs for patients with cancer. He has extensive experience in oncology clinical development. Dr. Kelsey served as Chief Medical Officer and Executive Vice President of Research & Development at Geron Corporation since April 27, 2009 and also served as its Head of R & D since May 2011. Dr. Kelsey served as Chief Medical Officer - Oncology of Geron Corporation, from April 27, 2009 to May 2011. Dr. Kelsey joined Geron from Genentech, Inc., where he served as Vice President of Clinical Hematology & Oncology and was responsible for a broad range of oncology development programs spanning pre-Phase I through marketed products. From 2002 to 2009, Dr. Kelsey held various positions at Genentech, Inc. Before his tenure at Genentech he served as Director of clinical affairs at Pharmacia Corporation (SUGEN, Inc.) in South San Francisco and Director of global clinical development (oncology) at Pharmacia Corporation in Milan, Italy. He also sits on the Scientific Advisory Boards of Autobahn Ventures and Remix Therapeutics. He previously served as Vice President of Hematology/Oncology at Genentech (part of the Roche Group) where he played a significant role in the development of key products including Perjeta®, Kadcyla® and Erivedge® as well as other molecules in the company’s oncology portfolio; and led clinical development for Pharmacia/SUGEN’s Sutent®. He was medical Director at Pharmacia /SUGEN (acquired by Pfizer). Dr. Kelsey was the lead clinician for both SU6668 and SU011248, which is now marketed as Sutent by Pfizer. He was a senior lecturer in hematology/oncology at St. Bartholomews and the Royal London School of Medicine and Dentistry. Dr. Kelsey is also Board certified in the European Union and British Columbia in Internal Medicine and Hematology/Oncology. He has over 100 peer-reviewed publications spanning cell biology, drug discovery, drug development and patient care and is a named inventor on several patents. Dr. Kelsey has B.S. in Pharmacology from University of Birmingham. Dr. Kelsey has M.D. from University of Birmingham. Dr. Kelsey has M.B.B.S. from University of Birmingham.

Positions